thiouracil and tyloxapol

thiouracil has been researched along with tyloxapol* in 1 studies

Other Studies

1 other study(ies) available for thiouracil and tyloxapol

Article	Year
Lipid-lowering effects of N-[4-methylbenzylthiocarbonyl]-L-phenylalanine (KF1492), a new phenylalanine derivative. Journal of pharmacobio-dynamics, 1982, Volume: 5, Issue:8 Lipid-lowering effects of KF1492, N-[4-methylbenzylthiocarbonyl]-L-phenylalanine, were evaluated in comparison with clofibrate. This compound lowered serum cholesterol (s-CL) and triglyceride(s-TG) in cholesterol-fed, Triton-injected and glycerol-fed rats as well as in normal rats. The dose of KF1492 required to show these effects was almost equal to that of clofibrate. In addition, KF1492 produced significant reductions of s-CL and s-TG in thiouracil-fed rats and decreasing phase of Triton-induced hyperlipemia of rats. In these models, clofibrate produced no significant reductions. Clofibrate produced a marked increase of liver size and shortened the pentobarbital-induced sleeping time in rats. On the contrary, the increase of liver size by KF1492 was less marked than clofibrate, and KF1492 caused no change in the sleeping time. Thus, it is apparent that KF1492 is a new lipid-lowering compound with less hepatic effect than clofibrate and that the lipid-lowering profile of KF1492 differs from that of clofibrate in some points. Topics: Animals; Cholesterol; Clofibrate; Diet; Glycerol; Hyperlipidemias; Hypolipidemic Agents; Male; Phenylalanine; Polyethylene Glycols; Rats; Rats, Inbred Strains; Thiouracil	1982

Article

Year

Lipid-lowering effects of N-[4-methylbenzylthiocarbonyl]-L-phenylalanine (KF1492), a new phenylalanine derivative.

Journal of pharmacobio-dynamics, 1982, Volume: 5, Issue:8

Lipid-lowering effects of KF1492, N-[4-methylbenzylthiocarbonyl]-L-phenylalanine, were evaluated in comparison with clofibrate. This compound lowered serum cholesterol (s-CL) and triglyceride(s-TG) in cholesterol-fed, Triton-injected and glycerol-fed rats as well as in normal rats. The dose of KF1492 required to show these effects was almost equal to that of clofibrate. In addition, KF1492 produced significant reductions of s-CL and s-TG in thiouracil-fed rats and decreasing phase of Triton-induced hyperlipemia of rats. In these models, clofibrate produced no significant reductions. Clofibrate produced a marked increase of liver size and shortened the pentobarbital-induced sleeping time in rats. On the contrary, the increase of liver size by KF1492 was less marked than clofibrate, and KF1492 caused no change in the sleeping time. Thus, it is apparent that KF1492 is a new lipid-lowering compound with less hepatic effect than clofibrate and that the lipid-lowering profile of KF1492 differs from that of clofibrate in some points.

Topics: Animals; Cholesterol; Clofibrate; Diet; Glycerol; Hyperlipidemias; Hypolipidemic Agents; Male; Phenylalanine; Polyethylene Glycols; Rats; Rats, Inbred Strains; Thiouracil

1982